Curcumin for Type 2 Diabetic Patients

• Status: Unknown status
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

There are evidence that there is an association between insulin resistance and prolonged hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide. This can contribute to a significant change in blood vessel and could end up with the complications from cardiovascular disease and increased mortality rate of type 2 diabetic patients. The purpose of the present study was to examine the effectiveness of the curcumin in type 2 diabetic patients on the reduction of atherosclerosis events by examining pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Srinakharinwirot University
• Collaborator: Ministry of Health, Thailand
• Treatments: Curcumin

Criteria

Inclusion Criteria:

• Diabetic patients aged 35 years or older and did not use insulin during the first 5 years of treatment after being diagnosed (with or without symptoms listed in the following inclusion criteria)

• Patient with hyperlipidemia (Cholesterol ≥ 200 mg/dl, TG ≥ 150 mg/dl, LDL ≥ 100 mg/dl and HDL ≥ 35 mg/dl)

• Patient with hypertension (Blood pressure ≥ 130/85 mmHg or take hypertensive drugs)

• Obesity (BMI ≥ 25)

Exclusion Criteria:

• Current diagnosis of secondary peripheral arterial disease (PAD) (except listed in the inclusion criteria item 1-4)

• Current diagnosis of cardiovascular disease, i.e., coronary arterial disease and cerebrovascular disease

• Current diagnosis of end stage renal function with serum creatinine > 2.0 mg/dl or on renal dialysis

• Current diagnosis of cirrhosis with ALT ≥ 3 times of normal range